SCHEMBL792959

SCHEMBL792959

CCc1cc(N)ncn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL28916507 0.88 NOS3 (0.39)
SCHEMBL2075967 0.82 NOS2 (0.47)
SCHEMBL1767952 0.82 HRH4 (0.41)
SCHEMBL12449394 0.79 NOS2 (0.50)
SCHEMBL17226870 0.78
SCHEMBL2052342 0.77 NOS2 (0.44)
Hydrochloric Acid SCHEMBL17372329 0.76 CA2 (0.40)
SCHEMBL12844206 0.76
SCHEMBL4872734 0.76 CYP1A2 (0.37)
SCHEMBL793127 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100508745-C A fencing VESTERGAARD CO LTD (DK) 2009-07-08 CN claimed
CN-1525815-A A fencing ֯ 2004-09-01 CN claimed
US-20250243193-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES SYNGENE INTERNATIONAL LIMITED (IN) 2025-07-31 US disclosed
CN-115697997-B Substituted 3-phenoxyazetidin-1-yl-pyrazines having GPR52 agonistic activity 勃林格殷格翰国际有限公司 2024-07-30 CN disclosed
EP-4126850-B1 SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES HAVING GPR52 AGONISTIC ACTIVITY BOEHRINGER INGELHEIM INT (DE) 2024-04-17 EP disclosed
US-11780827-B2 Substituted 3-phenoxyazetidin-1-yl-pyrazines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-10 US disclosed
US-11780827-B2 Substituted 3-phenoxyazetidin-1-yl-pyrazines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-10 US disclosed
US-11780827-B2 Substituted 3-phenoxyazetidin-1-yl-pyrazines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-10-10 US disclosed
EP-4126850-A1 SUBSTITUTED 3-PHENOXYAZETIDIN-1-YL-PYRAZINES HAVING GPR52 AGONISTIC ACTIVITY Boehringer Ingelheim International GmbH (DE) 2023-02-08 EP disclosed
CN-115697997-A Substituted 3-phenoxyazetidin-1-yl-pyrazines having GPR52 agonistic activity 勃林格殷格翰国际有限公司 2023-02-03 CN disclosed
US-20220356180-A1 AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL MYERS SQUIBB CO (US) 2022-11-10 US disclosed
CN-1525815-A A fencing ֯ 2004-09-01 CN disclosed
US-20040077875-A1 (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2 -thiazolyl)carbamic Acid, 1,1-dimethylethyl ester for example; treating immunological and oncological disorders such as inflammatory bowel disease or cancer DAS JAGABANDHU (US) 2004-04-22 US disclosed
US-20040073026-A1 Autoimmune diseases; anticancer agents DAS JAGABANDHU (US) 2004-04-15 US disclosed
US-20040054186-A1 Cyclic protein tyrosine kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-03-18 US disclosed
US-20040024208-A1 Drugs such as (5-(((2,4,6-Trimethylphenyl)amino)carbonyl)-4-methyl-2-thiazolyl)carbamic acid, 1,1-dimethylethyl ester, used as enzyme inhibitors, for prohylaxis of inflammatory bowel disease; modulation of immunology DAS JAGABANDHU (US) 2004-02-05 US disclosed
US-6596746-B1 protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders; dasatinib BRISTOL-MYERS SQUIBB COMPANY 2003-07-22 US disclosed
CN-1348370-A Cyclic protein tyrosine kinase inhibitors BRISTOL MYERS SQUIBB CO (US) 2002-05-08 CN disclosed
EP-1169038-A1 CYCLIC PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-01-09 EP disclosed
WO-2000062778-A1 CYCLIC PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB CO. (US) 2000-10-26 WO disclosed